The newly added in mechanism not only enhances our understanding of the clinical effectiveness of docetaxel and cabazitaxel in treating AR-driven CRPC, but also opens up possibilities for exploring improved treatments for various forms of prostate cancer. The gene discussed is AR; the disease is Familial prostate cancer.